Cargando…

Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1

INTRODUCTION: With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourafai-Aziez, Asma, Benabderrahmane, Mohammed, Paysant, Hippolyte, Weiswald, Louis-Bastien, Poulain, Laurent, Carlier, Ludovic, Ravault, Delphine, Jouanne, Marie, Coadou, Gaël, Oulyadi, Hassan, Voisin-Chiret, Anne-Sophie, Sopková-de Oliveira Santos, Jana, Sebban, Muriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688747/
https://www.ncbi.nlm.nih.gov/pubmed/34949914
http://dx.doi.org/10.2147/DDDT.S323077
_version_ 1784618409811509248
author Bourafai-Aziez, Asma
Benabderrahmane, Mohammed
Paysant, Hippolyte
Weiswald, Louis-Bastien
Poulain, Laurent
Carlier, Ludovic
Ravault, Delphine
Jouanne, Marie
Coadou, Gaël
Oulyadi, Hassan
Voisin-Chiret, Anne-Sophie
Sopková-de Oliveira Santos, Jana
Sebban, Muriel
author_facet Bourafai-Aziez, Asma
Benabderrahmane, Mohammed
Paysant, Hippolyte
Weiswald, Louis-Bastien
Poulain, Laurent
Carlier, Ludovic
Ravault, Delphine
Jouanne, Marie
Coadou, Gaël
Oulyadi, Hassan
Voisin-Chiret, Anne-Sophie
Sopková-de Oliveira Santos, Jana
Sebban, Muriel
author_sort Bourafai-Aziez, Asma
collection PubMed
description INTRODUCTION: With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affinity toward Mcl-1. RESULTS: A detailed NMR study revealed that only two of the five tested drugs, Torsemide and Deferasirox, interacted with Mcl-1. NMR data analysis allowed the complete characterization of the binding mode of both drugs to Mcl-1, including the estimation of their affinity for Mcl-1. Biological assays evidenced that the biological activity of Torsemide was lower as compared to the Deferasirox, which was able to efficiently and selectively inhibit the anti-apoptotic activity of Mcl-1. Finally, docking and molecular dynamics led to a 3D model for the Deferasirox:Mcl-1 complex and revealed the positioning of the drug in the Mcl-1 P2/P3 pockets as well as almost all synthetic Mcl-1 inhibitors. Interestingly, contrary to known synthetic Mcl-1 inhibitors which interact through Arg263, Deferasirox, establishes a salt bridge with Lys234. CONCLUSION: Deferasirox could be a potential candidate for drug repositioning as Mcl-1 inhibitor.
format Online
Article
Text
id pubmed-8688747
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86887472021-12-22 Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1 Bourafai-Aziez, Asma Benabderrahmane, Mohammed Paysant, Hippolyte Weiswald, Louis-Bastien Poulain, Laurent Carlier, Ludovic Ravault, Delphine Jouanne, Marie Coadou, Gaël Oulyadi, Hassan Voisin-Chiret, Anne-Sophie Sopková-de Oliveira Santos, Jana Sebban, Muriel Drug Des Devel Ther Original Research INTRODUCTION: With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affinity toward Mcl-1. RESULTS: A detailed NMR study revealed that only two of the five tested drugs, Torsemide and Deferasirox, interacted with Mcl-1. NMR data analysis allowed the complete characterization of the binding mode of both drugs to Mcl-1, including the estimation of their affinity for Mcl-1. Biological assays evidenced that the biological activity of Torsemide was lower as compared to the Deferasirox, which was able to efficiently and selectively inhibit the anti-apoptotic activity of Mcl-1. Finally, docking and molecular dynamics led to a 3D model for the Deferasirox:Mcl-1 complex and revealed the positioning of the drug in the Mcl-1 P2/P3 pockets as well as almost all synthetic Mcl-1 inhibitors. Interestingly, contrary to known synthetic Mcl-1 inhibitors which interact through Arg263, Deferasirox, establishes a salt bridge with Lys234. CONCLUSION: Deferasirox could be a potential candidate for drug repositioning as Mcl-1 inhibitor. Dove 2021-12-15 /pmc/articles/PMC8688747/ /pubmed/34949914 http://dx.doi.org/10.2147/DDDT.S323077 Text en © 2021 Bourafai-Aziez et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bourafai-Aziez, Asma
Benabderrahmane, Mohammed
Paysant, Hippolyte
Weiswald, Louis-Bastien
Poulain, Laurent
Carlier, Ludovic
Ravault, Delphine
Jouanne, Marie
Coadou, Gaël
Oulyadi, Hassan
Voisin-Chiret, Anne-Sophie
Sopková-de Oliveira Santos, Jana
Sebban, Muriel
Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
title Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
title_full Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
title_fullStr Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
title_full_unstemmed Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
title_short Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
title_sort drug repurposing: deferasirox inhibits the anti-apoptotic activity of mcl-1
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688747/
https://www.ncbi.nlm.nih.gov/pubmed/34949914
http://dx.doi.org/10.2147/DDDT.S323077
work_keys_str_mv AT bourafaiaziezasma drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT benabderrahmanemohammed drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT paysanthippolyte drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT weiswaldlouisbastien drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT poulainlaurent drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT carlierludovic drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT ravaultdelphine drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT jouannemarie drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT coadougael drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT oulyadihassan drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT voisinchiretannesophie drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT sopkovadeoliveirasantosjana drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1
AT sebbanmuriel drugrepurposingdeferasiroxinhibitstheantiapoptoticactivityofmcl1